{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T15:59:46Z","timestamp":1791129586278,"version":"4.1.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Incozen Therapeutics Pvt Ltd"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.jpba.2014.11.041","type":"journal-article","created":{"date-parts":[[2014,12,25]],"date-time":"2014-12-25T09:33:29Z","timestamp":1419500009000},"page":"151-158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC\u2013MS\/MS: Application to a pharmacokinetic study"],"prefix":"10.1016","volume":"107","author":[{"given":"Sridhar","family":"Veeraraghavan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srikant","family":"Viswanadha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satheeshmanikandan","family":"Thappali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babu","family":"Govindarajulu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swaroopkumar","family":"Vakkalanka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manivannan","family":"Rangasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2014.11.041_bib0110","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1038\/nri955","article-title":"Regulation of B-cell fate by antigen-receptor signals","volume":"2","author":"Niiro","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jpba.2014.11.041_bib0115","doi-asserted-by":"crossref","first-page":"5715","DOI":"10.4049\/jimmunol.176.10.5715","article-title":"Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma","volume":"176","author":"Gururajan","year":"2006","journal-title":"J. Immunol."},{"key":"10.1016\/j.jpba.2014.11.041_bib0120","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrc1589","article-title":"Mechanisms of B-cell lymphoma pathogenesis","volume":"5","author":"K\u00fcppers","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jpba.2014.11.041_bib0125","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jpba.2014.11.041_bib0130","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","article-title":"Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia","volume":"107","author":"Eichhorst","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jpba.2014.11.041_bib0135","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"Keating","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jpba.2014.11.041_bib0140","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"Rai","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jpba.2014.11.041_bib0145","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1182\/blood-2010-11-315705","article-title":"The role of phosphatidylinositol 3-kinase-\u03b4 in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia","volume":"117","author":"Herman","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jpba.2014.11.041_bib0150","doi-asserted-by":"crossref","first-page":"30644","DOI":"10.1074\/jbc.274.43.30644","article-title":"Syk and Bruton's tyrosine kinase are required for B cell antigen receptor-mediated activation of the kinase akt","volume":"274","author":"Craxton","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jpba.2014.11.041_bib0155","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2172-2-4","article-title":"A conditional form of Bruton's tyrosine kinase is sufficient to activate multiple downstream signaling pathways via PLC Gamma 2 in B cells","volume":"2","author":"Tomlinson","year":"2001","journal-title":"BMC Immunol."},{"key":"10.1016\/j.jpba.2014.11.041_bib0160","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1084\/jem.191.10.1745","article-title":"Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement","volume":"191","author":"Petro","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jpba.2014.11.041_bib0165","doi-asserted-by":"crossref","first-page":"13075","DOI":"10.1073\/pnas.1004594107","article-title":"The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy","volume":"107","author":"Honigberg","year":"2010","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jpba.2014.11.041_bib0170","doi-asserted-by":"crossref","first-page":"203","DOI":"10.18632\/oncotarget.426","article-title":"Novel targeted therapies for mantle cell lymphoma","volume":"3","author":"Alinari","year":"2012","journal-title":"Oncotarget"},{"key":"10.1016\/j.jpba.2014.11.041_bib0175","series-title":"ASH Annual Meeting Abstracts","author":"Fowler","year":"2010"},{"key":"10.1016\/j.jpba.2014.11.041_bib0180","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nrd3656","article-title":"Trial watch: BTK inhibitor shows positive results in B cell malignancies","volume":"11","author":"Harrison","year":"2012","journal-title":"Nat. Rev. Drug Discovery"},{"key":"10.1016\/j.jpba.2014.11.041_bib0185","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1039\/c2an36701g","article-title":"Development and validation of LC\u2013MS\/MS method for the quantitation of lenalidomide in human plasma using Box\u2013Behnken experimental design","volume":"138","author":"Hasnain","year":"2013","journal-title":"Analyst"},{"key":"10.1016\/j.jpba.2014.11.041_bib0190","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1752-153X-7-52","article-title":"Trace determination of lenalidomide in plasma by non-extractive HPLC procedures with fluorescence detection after pre-column derivatization with fluorescamine","volume":"7","author":"Khalil","year":"2013","journal-title":"Chem. Cent. J."},{"key":"10.1016\/j.jpba.2014.11.041_bib0195","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1097\/FTD.0b013e318185813d","article-title":"Development and validation of a highly sensitive liquid chromatography\/mass spectrometry method for simultaneous quantification of lenalidomide and flavopiridol in human plasma","volume":"30","author":"Liu","year":"2008","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2014.11.041_bib0200","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s00280-011-1781-y","article-title":"Plasma and cerebrospinal fluid pharmacokinetics of thalidomide and lenalidomide in nonhuman primates","volume":"69","author":"Muscal","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jpba.2014.11.041_bib0205","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jchromb.2014.01.001","article-title":"Simultaneous quantification of idelalisib, fludarabine and lenalidomide in rat plasma by using high-performance liquid chromatography coupled with heated electrospray ionization tandem mass spectrometry","volume":"949\u2013950","author":"Veeraraghavan","year":"2014","journal-title":"J. Chromatogr. B, Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2014.11.041_bib0210","series-title":"Guidance for Industry, Bioanalytical Method Validation","author":"US Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research (CDER)","year":"2001"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708514005779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708514005779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,18]],"date-time":"2019-08-18T20:49:05Z","timestamp":1566161345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708514005779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":21,"alternative-id":["S0731708514005779"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2014.11.041","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous quantification of lenalidomide, ibrutinib and its active metabolite PCI-45227 in rat plasma by LC\u2013MS\/MS: Application to a pharmacokinetic study","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2014.11.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}